# CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19

> **NCT04516941** · PHASE3 · TERMINATED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 60 (actual)

## Conditions studied

- SARS-CoV Infection
- COVID-19

## Interventions

- **DRUG:** Edoxaban Tablets
- **DRUG:** Colchicine Tablets

## Key facts

- **NCT ID:** NCT04516941
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-21
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Insufficient rate of patient accrual and newly available scientific evidence
- **Last updated:** 2022-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04516941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04516941, "CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04516941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*